Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Rhea-AI Summary

Palatin Technologies, Inc. announced the database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease. The top-line results are expected to be reported later in February. The trial is a multi-center, randomized, double–masked and vehicle–controlled study, that enrolled 575 patients at sites in the U.S. The Phase 3 program also includes the Phase 3 safety and efficacy study MELODY-2 and the open label MELODY-3 study, which are anticipated to commence patient enrollment in the second half of calendar year 2024.

Medical Research Analyst

The announcement by Palatin Technologies regarding the database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial signifies a critical juncture in the development of a potential new treatment for dry eye disease (DED). The focus on melanocortin receptor modulation is notable, as this represents a novel therapeutic approach distinct from current treatments that typically target tear production or inflammation. The trial's design, with its co-primary endpoints addressing both a clinical sign and symptom of DED, aligns with the FDA's guidance for a comprehensive assessment of therapeutic efficacy.

Investors should note that the success of MELODY-1 hinges on the achievement of these co-primary endpoints. The hierarchical testing strategy for secondary endpoints is a rigorous method that ensures the statistical robustness of the trial's findings. However, the complexity of DED, which can be influenced by a myriad of environmental and physiological factors, adds a layer of uncertainty to the trial outcomes. The trial's results will not only impact the company's stock but also set a precedent for future treatments targeting the melanocortin receptor system.

Financial Analyst

The impending release of top-line results from the MELODY-1 trial is poised to have a significant effect on Palatin Technologies' market valuation. Given that the trial's outcome can potentially lead to a New Drug Application (NDA), positive results could catalyze investor confidence and drive up the company's share price. Conversely, failure to meet the co-primary endpoints could lead to a decline in investor sentiment. As the company is still in the clinical stage, its revenue stream is highly contingent upon the successful progression of its pipeline products, making this trial's results a pivotal financial event.

The biopharmaceutical sector is known for its high volatility around such clinical trial announcements and Palatin's stock may experience increased trading volume and price swings. Investors should be aware of the inherent risks of investing in biopharmaceutical companies, where the commercial success of their products is uncertain until regulatory approval is secured and market adoption is achieved.

Market Research Analyst

Dry eye disease represents a significant market opportunity, with a growing prevalence attributed to an aging population and lifestyle factors such as increased screen time. The development of PL9643 by Palatin Technologies could potentially address an unmet medical need within the DED market, which is currently dominated by a limited number of therapeutic options. Should the MELODY-1 trial demonstrate positive efficacy and safety, PL9643 could disrupt the existing market dynamics.

Furthermore, the trial's success could attract partnership opportunities, offering strategic advantages such as shared risks and expanded commercialization capabilities. The market will be observing how Palatin positions PL9643 in a competitive landscape and whether it can secure a favorable market share against established treatments. Long-term market potential will also hinge on the outcomes of the subsequent MELODY-2 and MELODY-3 studies, which will further elucidate the drug's safety and efficacy profile.

Top-Line Results Expected in February

CRANBURY, N.J., Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).

MELODY-1 has two co-primary efficacy endpoints: one clinical sign of DED and one clinical symptom of DED. If one or both co-primary end points are met, the study will be deemed a success and the secondary end points will be evaluated using a hierarchical testing strategy.

"We are excited by the database lock and that data analysis by the independent statisticians has commenced. We look forward to reporting top-line results from the PL9643 MELODY-1 pivotal Phase 3 clinical trial later in February," said Carl Spana, Ph.D., President and CEO of Palatin. "I want to thank our clinical team, our study sites and our independent service firms for their dedication and collaborative efforts."

The pivotal Phase 3 MELODY-1 trial is a multi-center, randomized, double–masked and vehicle–controlled study, that enrolled 575 patients at sites in the U.S. The trial evaluated the safety and efficacy of the melanocortin agonist, PL9643 ophthalmic solution, compared to vehicle in patients with moderate-to-severe DED, for multiple sign and symptom endpoints, after treatment for 12 weeks. The study design was based on positive Phase 2 results of PL9643 for the treatment of DED, and an end-of-Phase 2 meeting with the FDA on key elements of the pivotal Phase 3 clinical program.

The remainder of the Phase 3 program, which includes the Phase 3 safety and efficacy study MELODY-2 and the open label MELODY-3 study are anticipated to commence patient enrollment in the second half of calendar year 2024.

About Dry Eye Disease (DED)
Dry eye disease is a common inflammatory disease that, left untreated, can become extremely painful and lead to permanent damage to the cornea and vision. DED affects the cornea and conjunctiva of the eye resulting in irritation, redness, pain, and blurred vision. It is estimated to affect over 20 million people in the United States. The disease is characterized by insufficient moisture and lubrication in the anterior surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, diminished quality of life, and in severe cases, permanent vision impairment. Existing therapy for DED is generally regarded as inadequate by many physicians and patients, and often requires weeks or months to demonstrate activity.

About Melanocortin Receptor Agonists and Inflammation
The melanocortin receptor ("MCr") system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function. There are five melanocortin receptors, MCR1 through MCR5. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects.

Many tissues and immune cells located in the eye (and other places, for example the gut and kidney) express melanocortin receptors, empowering our opportunity to directly activate natural pathways to resolve disease inflammation.

About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. To learn more about Palatin, please visit us on www.Palatin.com and follow us on Twitter at @PalatinTech.

Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about Palatin products in development, clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates, and market potential for product candidates are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory agencies and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.

Palatin Technologies^® is a registered trademark of Palatin Technologies, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-announces-database-lock-for-pl9643-melody-1-pivotal-phase-3-clinical-trial-in-patients-with-dry-eye-disease-ded-302052721.html

SOURCE Palatin Technologies, Inc.

FAQ

What is the ticker symbol of Palatin Technologies, Inc.?

The ticker symbol of Palatin Technologies, Inc. is PTN.

What is the purpose of the PL9643 MELODY-1 pivotal Phase 3 clinical trial?

The purpose of the PL9643 MELODY-1 pivotal Phase 3 clinical trial is to evaluate the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease.

How many patients were enrolled in the MELODY-1 trial?

The MELODY-1 trial enrolled 575 patients at sites in the U.S.

When are the top-line results from the PL9643 MELODY-1 trial expected to be reported?

The top-line results from the PL9643 MELODY-1 trial are expected to be reported later in February.

What other studies are included in the Phase 3 program?

The Phase 3 program includes the Phase 3 safety and efficacy study MELODY-2 and the open label MELODY-3 study, which are anticipated to commence patient enrollment in the second half of calendar year 2024.